[{"bbox": [91, 99, 368, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [662, 171, 985, 199], "category": "Section-header", "text": "# OBJECTS OF THE ISSUE"}, {"bbox": [91, 233, 1557, 298], "category": "Text", "text": "The Issue includes a fresh Issue of up to 70,53,200 Equity Shares of our Company at an Issue Price of Rs. [●] per Equity Share. We intend to utilize the proceeds of the Issue to meet the following objects: -"}, {"bbox": [91, 331, 575, 361], "category": "List-item", "text": "1) To meet Working Capital requirements"}, {"bbox": [91, 363, 945, 393], "category": "List-item", "text": "2) Repayment of certain borrowing availed by our Company, in part or full"}, {"bbox": [91, 395, 453, 426], "category": "List-item", "text": "3) General Corporate Purpose."}, {"bbox": [91, 458, 535, 490], "category": "Text", "text": "*(Collectively referred as the “Objects”)*"}, {"bbox": [91, 521, 1560, 710], "category": "Text", "text": "We believe that listing will enhance our corporate image and visibility of brand name of our Company. We also believe that our Company will receive the benefits from listing of Equity Shares on the SME platform of NSE (NSE EMERGE). It will also provide liquidity to the existing shareholders and will also create a public trading market for the Equity Shares of our Company. The main object clause of our Memorandum of Association and the objects incidental and ancillary to the main objects enables us to undertake the activities for which funds are being raised in the Issue. The existing activities of our Company are within the objects clause of our Memorandum of Association."}, {"bbox": [91, 745, 1560, 969], "category": "Text", "text": "We are engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. Our company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of Q-Line in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids)."}, {"bbox": [91, 1002, 248, 1030], "category": "Section-header", "text": "## Net Proceeds"}, {"bbox": [91, 1064, 662, 1093], "category": "Text", "text": "The details of the Net Proceeds are set forth below:"}, {"bbox": [1348, 1096, 1557, 1124], "category": "Text", "text": "(Amt. Rs. in Lacs)"}, {"bbox": [91, 1124, 1557, 1260], "category": "Table", "text": "<table><thead><tr><td>Particulars</td><td>Amount</td></tr></thead><tbody><tr><td>Gross Proceeds of the Issue</td><td>[●]<sup>(1)</sup></td></tr><tr><td>Less: Issue related expenses in relation to Issue*</td><td>[●]</td></tr><tr><td>Net Proceeds</td><td>[●]</td></tr></tbody></table>"}, {"bbox": [91, 1263, 1357, 1293], "category": "Text", "text": "*To be finalized upon determination of the Issue Price and updated in the Prospectus Prior to filing with the RoC."}, {"bbox": [91, 1295, 1560, 1583], "category": "Text", "text": "(1) Includes the proceeds, if any, received pursuant to the Pre-IPO Placement which may be undertaken, in consultation with the BRLMs. The Pre-IPO Placement, if undertaken, will be at a price to be decided by our Company, in consultation with the BRLMs. If the Pre-IPO Placement is completed, the amount raised pursuant to the Pre-IPO Placement will be reduced from the Issue, subject to compliance with Rule 19(2)(b) of the SCRR. The Pre-IPO Placement, if undertaken, shall not exceed 20% of the size of the Fresh Issue. Prior to the completion of the Issue, our Company shall appropriately intimate the subscribers to the Pre-IPO Placement, prior to allotment pursuant to the Pre-IPO Placement, that there is no guarantee that our Company may proceed with the Issue or the Issue may be successful and will result into listing of the Equity Shares on the Stock Exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the Pre-IPO Placement (if undertaken) shall be appropriately made in the relevant sections of the RHP and Prospectus."}, {"bbox": [91, 1616, 736, 1645], "category": "Section-header", "text": "## Requirement of Funds and Utilization of Net Proceeds"}, {"bbox": [91, 1678, 1107, 1708], "category": "Text", "text": "The Net Proceeds are proposed to be used in accordance with the details as set forth below:"}, {"bbox": [1348, 1711, 1557, 1739], "category": "Text", "text": "(Amt. Rs. in Lacs)"}, {"bbox": [91, 1739, 1557, 1908], "category": "Table", "text": "<table><thead><tr><td>S. No</td><td>Particulars</td><td>Amount</td></tr></thead><tbody><tr><td>1</td><td>To meet Working Capital requirements</td><td>11000.00</td></tr><tr><td>2</td><td>Repayment of certain borrowing availed by our Company, in part or full</td><td>9000.00</td></tr><tr><td>3</td><td>General Corporate Purpose*</td><td>[●]</td></tr><tr><td></td><td>Total</td><td>[●]</td></tr></tbody></table>"}, {"bbox": [91, 1912, 1557, 1974], "category": "Text", "text": "Includes the proceeds, if any, received pursuant to the Pre-IPO Placement. Upon allotment of securities pursuant to the Pre-IPO Placement, our Company shall utilize the proceeds from such Pre-IPO Placement towards the Objects of the Issue."}, {"bbox": [91, 1976, 1557, 2037], "category": "Text", "text": "*To be finalized upon determination of the Issue Price and updated in the Prospectus prior to filing with the RoC. The amount utilized for general corporate purposes shall not exceed 15% of the Gross Proceeds or Rs. 10 crores whichever is lower."}, {"bbox": [91, 2070, 303, 2099], "category": "Section-header", "text": "## Means of Finance"}, {"bbox": [91, 2135, 1090, 2164], "category": "Text", "text": "We intend to finance our Objects of Issue through Net Issue Proceeds which is as follows:"}, {"bbox": [810, 2172, 840, 2200], "category": "Page-footer", "text": "86"}]